Affimed

Affimed NV engages in the discovery and development of cancer immunotherapies. It is a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer by actualizing the untapped potential of the innate immune system. The company’s proprietary ROCK platform enables a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors, enabling a broad pipeline of wholly-owned and partnered single agent and combination therapy programs. The ROCK platform predictably generates customized innate cell engager molecules, which use patient's immune cells to destroy tumor cells. The company was founded in 2000 and is headquartered in Heidelberg, Germany.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Affimed reports Q1 loss, positive clinical data in cancer treatments

Affimed's Q1 2024 performance showed a net loss but highlighted positive clinical data and progress in cancer treatments.
Despite enrollment delays in the LuminICE trial, Affimed's programs leveraging the innate immune system demonstrate consistency and success.
Addressing financial challenges, patient enrollment issues, and leveraging opportunities in future study phases and partnerships are key for Affimed's growth.

Affimed reports Q3 performance, highlights clinical milestones, and eyes partnerships

Affimed's Q3 2024 performance reflects a net loss of EUR 15.1 million but maintains a solid cash position of EUR 24.1 million.
Management's focus on clinical milestones, safety profiles, and upcoming updates at ASH 2024 demonstrates a commitment to innovation.
Challenges lie in meeting data expectations, navigating partnerships, and balancing financial stability with growth aspirations.
Opportunities abound in showcasing progress at ASH 2024, exploring partnerships, and advancing clinical programs for future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Affimed NV is a clinical-stage immuno-oncology company, which engages in the discovery and development of cancer immunotherapies. The company’s proprietary ROCK platform enables a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors, enabling a broad pipeline of wholly-owned and partnered single agent and combination therapy programs. It operates through the Germany and USA geographical segments. The company was founded in 2000 and is headquartered in Mannheim, Germany.

Affimed N.V. (AFMD) CEO Adi Hoess on Q4 2021 Results - Earnings Call Transcript

HEIDELBERG, Germany, March 31, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today reported financial results for the year ended December 31, 2021, and provided an update on clinical and corporate progress.

Affimed Reports 2021 Financial Results and Highlights Recent Operational Progress

HEIDELBERG, Germany, March 24, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it will release full year 2021 results and corporate update on Thursday, March 31, 2022. The Company will host a conference call at 8:30 a.m. Eastern Daylight Time.

Affimed to Report Full Year 2021 Financial Results & Corporate Update on March 31, 2022

HEIDELBERG, Germany, March 08, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that two abstracts with clinical data of its innate cell engagers (ICE®) have been accepted for presentation at the annual meeting of the American Association for Cancer Research (AACR), taking place April 8-13, 2022 in New Orleans, Louisiana.

Affimed Announces Clinical Updates at the Annual Meeting of the American Association for Cancer Research

HEIDELBERG, Germany, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced the publication of pre-clinical data demonstrating the cytotoxic potency and efficacy of NK cells precomplexed with ICE® molecules after one cycle of cryopreservation. This is an important prerequisite for the development of off-the-shelf products which may allow accessibility to the novel treatment option for patients in need.

Affimed Announces Publication of Preclinical Data Demonstrating Cytotoxic Potency and Efficacy of NK Cells Precomplexed with Innate Cell Engagers after Freezing & Thawing

HEIDELBERG, Germany, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that management will present and host one-on-one meetings at the following investor conferences during the month of February 2022.

Affimed to Present at Upcoming Investor Events

Doximity

Novocure

Here's why our roundtable is excited about Doximity, Novocure, and Affimed.

3 Amazing Stocks That Are 60% Off Their Highs

HEIDELBERG, Germany, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it has completed enrollment in the REDIRECT study and provided a business update.

Affimed Announces Completion of Enrollment in REDIRECT, the Registration-Directed Study of AFM13 in PTCL, and Provides Business Update

HEIDELBERG, Germany, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that its Chief Executive Officer Dr. Adi Hoess will present at the 40th Annual J.P. Morgan Healthcare Conference on Thursday, January 13, 2022 at 10:30 a.m. Eastern Standard Time / 16:30 Central European Time.

Affimed to Present at the 40th Annual J.P. Morgan Healthcare Conference

HEIDELBERG, Germany, Dec. 13, 2021 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today presented preclinical data from two of their Innate Cell Engager (ICE®) programs at the 63rd American Society of Hematology Annual Meeting (ASH). The poster presentations included preclinical proof-of-concept data on AFM28, for which Affimed recently revealed the target and indication. The program is in development for the treatment of Acute Myeloid Leukemia and other CD123+ hematologic malignancies. The second poster presentation provided data on the activity of AFM13 pre-complexed to NK cells after cryopreservation, demonstrating the potential to develop AFM13 as an off-the-shelf chimeric antigen receptor (CAR)-like NK cell product.

Affimed Shares Preclinical Data on Innate Cell Engagers AFM28 and AFM13 at the 63rd American Society of Hematology Annual Meeting and Exposition

Roche Holding AG

Affimed (AFMD) starts recruiting patients in a phase I/IIa study to evaluate the combination of AFM24 and Roche's atezolizumab in solid tumors.

Affimed (AFMD) Starts AFM24-102 Study With Roche's Tecentriq

HEIDELBERG, Germany, Dec. 09, 2021 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer will host today a financial community call to discuss recent findings from the investigator sponsored trial (IST) at The University of Texas MD Anderson Cancer Center investigating the treatment of CD30-positive lymphoma patients with its innate cell engager (ICE®) AFM13, pre-complexed with cord blood-derived natural killer (cbNK) cells (AFM13-104).

Affimed to Host Virtual Investor Call Today to Discuss Treatment of CD30-positive Lymphoma Patients with Cord Blood-derived Natural Killer Cells Pre-complexed with Innate Cell Engager AFM13

HEIDELBERG, Germany, Dec. 08, 2021 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today the initiation of patient recruitment for the open-label, multi-center phase 1/2a study evaluating the safety, tolerability, pharmacokinetics and efficacy of the innate cell engager (ICE®) AFM24 in combination with Roche's atezolizumab, an anti-PD-L1 checkpoint inhibitor. AFM24 is Affimed's tetravalent, bispecific epidermal growth factor receptor (EGFR)- and CD16A-targeting ICE®, developed for the treatment of patients with solid tumors.

Affimed Initiates Patient Recruitment for a Phase 1/2a Trial of Innate Cell Engager AFM24 in Combination with Roche's Anti-PD-L1 Checkpoint Inhibitor Atezolizumab

Adaptimmune Therapeutics

Aurinia Pharmaceuticals

Axsome Therapeutics

BridgeBio Pharma Inc

BioCryst Pharmaceuticals

Beam Therapeutics

Amicus Therapeutics

SPDR S&P Biotech ETF

These eight stocks could rebound nicely over the next year and beyond.

8 Beaten-Down Pharmaceutical Stocks That Could Skyrocket In 2022

Amgen

Bristol-Myers

Affimed, Amgen, and Bristol Myers Squibb are too cheap to ignore right now.

3 Best Biopharma Stocks to Buy During This Industrywide Fire Sale

Affimed NV (NASDAQ:AFMD) has announced interim clinical results from the investigator-initiated Phase 1/2 study evaluating cbNK cells pre-complexed with Affimed's innate cell engager (ICE) AFM13. Eighteen patients with CD30-positive relapsed or refractory Hodgkin and non-Hodgkin lymphomas were treated with the combination of cbNK cells pre-complexed with AFM13.

Affimed's Lymphoma Candidate Shows 100% Objective Response Rate At Highest Dose

The biotech's early-stage trial results are turning heads on Wall Street today.

Why Affimed Stock Is On Fire Today

HEIDELBERG, Germany, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced interim clinical results from the investigator-initiated phase 1-2 study at The University of Texas MD Anderson Cancer Center, evaluating cbNK cells pre-complexed with Affimed's innate cell engager (ICE®) AFM13.

Affimed Announces 100% Objective Response Rate at Highest Dose in Phase 1-2 Study of Cord Blood-derived Natural Killer Cells Pre-complexed with Innate Cell Engager AFM13 for CD30-positive Lymphomas

Positive trial results regarding the company's pipeline are buoying the stock's price.

Why Affirmed Stock Was Up More Than 12% Wednesday

HEIDELBERG, Germany, Nov. 12, 2021 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that three posters with preclinical data of its innate cell engagers (ICE®) are presented at the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC). The data highlight Affimed's preclinical initiatives to further elucidate the mechanisms of action for its lead ICE® candidates AFM13 and AFM24, providing evidence that both ICE® molecules increased the number of NK cells which functioned as serial killers against cancer as well as the role of macrophages in the anti-tumor activity of AFM24.

Affimed Shares Preclinical Data on Mechanism of Action of two Innate Cell Engagers at the 36th SITC Meeting, Demonstrating their Potential to Induce Antibody Dependent Cellular Phagocytosis and Serial Killing

Affimed N.V. (AFMD) CEO Adi Hoess on Q3 2021 Results - Earnings Call Transcript

Affimed N.V. (AFMD) delivered earnings and revenue surprises of -30.77% and -13.34%, respectively, for the quarter ended September 2021.

Affimed N.V. (AFMD) Reports Q3 Loss, Lags Revenue Estimates

Affimed (NASDAQ:AFMD) reported its Q3 earnings results on Wednesday, November 10, 2021 at 08:00 AM. Here's what investors need to know about the announcement.

Recap: Affimed Q3 Earnings

HEIDELBERG, Germany, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today reported financial results for the quarter ended September 30, 2021, and provided an update on clinical and corporate progress.

Affimed Reports Third Quarter 2021 Financial Results and Highlights Operational Progress

HEIDELBERG, Germany and SANTA ANA, Calif., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) and NKGen Biotech, both clinical stage biotech companies focused on harnessing the power of the body's innate immune system, announced today the initiation of patient recruitment in the open-label, multi-center phase 1/2a study (NCT05099549) evaluating the safety, tolerability, and anti-tumor activity of the innate cell engager (ICE®) AFM24 (Affimed's tetravalent, bispecific epidermal growth factor receptor (EGFR)- and CD16A-binding ICE®) in combination with SNK01 (ex vivo expanded and activated autologous NK cell therapy from NKGen Biotech).

Affimed and NKGen Biotech Announce Initiation of Patient Recruitment in a First-in-human Phase 1/2a Trial of Innate Cell Engager AFM24 in Combination with Autologous NK Cell Product SNK01

News for Affimed Stock (AFMD)